NASDAQ OMX

Zageno Surpasses its Growth Targets in First Half of 2018; Adds Resources and Structures to Accelerate Growth for the Rest of the Year

Dela

New Hires Include VP, Finance Johann du Toit and VP, U.S. Sales Rafael Casiano ·Headquarters Moves to Cambridge, Mass. USA

CAMBRIDGE, Mass. USA and BERLIN, Germany, June 27, 2018 (GLOBE NEWSWIRE) -- Zageno Inc., an online biotech marketplace, has quadrupled sales in the first half of 2018, exceeding its planned growth trajectory for the year. Chief Executive Officer David Pumberger, Ph.D., attributing success to date to the company's customer-centric culture, announces plans to accelerate growth in the second half of the year. These include: an expanded leadership team comprising key hires in critical positions, bolstered processes and operations so Zageno can extend its high level of responsiveness to an ever-growing list of customer and vendor partners, and a headquarter move to Cambridge, Massachusetts.

"It may sound trite, but we really care about our customers, and it shows," said Pumberger. "Ask them what made them try Zageno for the very first time and there's a good chance they can't tell you: 'Hmm.I saw magnets with the Zageno name everywhere? I heard about it from a friend? To tell you the truth, I can't remember.'

"But if you ask about their experience, their answer is some variation of this: 'I love Zageno's people. I use the chat function or talk to a real person on the phone. And even when I'm not particularly happy because something's not going my way - they work hard to find a quick resolution. It's always a pleasant interaction - and that's so unusual today.'"

Pumberger added, "It may seem counterintuitive for what's, in theory, a 'virtual' company, but one of the founding principles behind Zageno is that close interpersonal connection we develop with our customers to help them succeed. We are committed to building this as we grow, which is why we decided to move our headquarters to the biotech hub of Cambridge - home to many of our key stakeholders: major U.S. academic research institutions, pharma and biotech companies and vendors, and life-science startups.

"It's why we've been adding experienced scientists across the spectrum of research to our customer-service group, and why we are expanding our leadership team." The founders' hiring goal, according to Pumberger: bring in individuals with the experience, skills, and demonstrated track record the company needs so it can delight existing and new customers and vendor partners with even better product offerings and services - while positioning Zageno for accelerated growth and the company's next stage of development.

Johann du Toit and Rafael Casiano will provide the backbone of the company's enhanced administrative and commercial structure as vice presidents of finance and U.S. sales, respectively.

With increased revenues, expanded vendor contracts, and plans for securing additional capital in the company's future, Zageno is formalizing key aspects of its operations. Johann du Toit will be joining Zageno August 1st, bringing a broad range of global finance experience to his charge of building the company's finance function with a modernized approach to facilitating international payment flows, cost control, and more transparency to internal and external stakeholders. He has well-rounded leadership experience, managing projects at Ernst & Young, KPMG, and IKB Deutsche Industriebank, where his mastery of financial modeling proved to be indispensable for his clients' strategy decisions. Most recently, du Toit has taken on interim CFO roles to help several small to medium enterprises to raise funds and streamline their finance functions, among other critical tasks for companies on a rapid growth trajectory. He is a chartered accountant [CA/(SA)], and holds an executive master's in business administration (EMBA) from IE Business School, specializing in entrepreneurship, and a bachelor's degree in finance, accounting, tax, and auditing from the University of Pretoria in South Africa.

Zageno will develop repeatable sales processes under the leadership of Rafael Casiano, who joined Zageno in May. He began his career in the laboratory as a microbiologist at the Florida Department of Agriculture and subsequently led the QC lab for Pall Corporation, where he transitioned to a key account manager position and found his passion in sales and business development. For more than 20 years, Casiano approached his commercial roles successfully as a tenacious customer advocate, amassing deep relationships throughout pharmaceutical, biotechnology, and academic markets. As a global commercial leader at GE Healthcare, he developed commercial processes, combining sales and project-management disciplines to help advance cancer biomarker discovery. He holds a bachelor's degree in microbiology from the University of South Florida.

Chief Revenue Officer Florian Wegener, M.D., Ph.D., M.B.A., commented, "I'm excited to bring in new leadership who will enhance our company culture. We want customers to be able to remember their first personal interaction with Zageno and to tell their colleagues that we were right beside them when we simplified their administrative tasks, integrated into their existing processes, saving them time and money - resolving issues and needs they didn't even know they had."   

About Zageno Inc. ( www.zageno.com ;  twitter:  @ZAGENOteam )

Founded in 2015, Zageno is eliminating bottlenecks to breakthrough science and research through curated connections linking scientists and their institutions' procurement offices with leading life-science vendors. World-renowned academic and government research facilities, global pharmaceutical companies, and biotechs large and small are already users of our unique online biotech marketplace, currently comprising about five million products. What do we do? 1) We make purchasing transactions more efficient for both buyers and sellers. 2) We help scientists choose the optimal laboratory kits and materials for each unique experiment setup. 3) We provide a valuable, expanded sales channel for our vendor partners. The growing Zageno team of 60 in Cambridge, USA, and Berlin, Germany, includes accessible experts in science, e-commerce, systems integration, and customer support. Our people work directly with customers to enable smarter, faster processes - allowing more time and resources for value-added science and better research results. 

Attachment

Caroline Grossman, Communications & Public Affairs, Mirepoix LLC

ZAGENO, Inc.

(781) 771-5579

caroline@mirepoixllc.com

 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ZAGENO, Inc. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Bergman & Beving AB: Share-based incentive scheme25.9.2018 10:00Pressmeddelande

Press Release Share-based incentive scheme The share-based incentive scheme resolved by the 2018 Annual General Meeting where 16 members of senior management were offered to acquire up to 210,000 call options on repurchased class B shares has been fully subscribed. The call options will be transferred at a price of SEK 7.10 per call option, equivalent to the market value according to an external independent valuation, applying the Black-Scholes-model. The redemption price of the call options amounts to SEK 117.90, equivalent to 120 percent of the volume-weighted average of the paid market price for the shares during the period from 24 August to 7 September 2018, inclusive. Each call option entitles the holder to acquire one repurchased class B share during the period from 13 September 2021 to 10 June 2022, inclusive. Stockholm den 25 September 2018 Bergman & Beving AB (publ) Contact information Peter Schön, CFO, Bergman & Beving AB, Tel: +46 70 339 89 99 The information was submitted f

Bergman & Beving AB: Aktierelaterat incitamentsprogram25.9.2018 10:00Pressmeddelande

Pressrelease Aktierelaterat incitamentsprogram Det av årsstämman 2018 beslutade aktierelaterade incitamentsprogrammet som omfattar 16 ledningspersoner om maximalt 210 000 köpoptioner på återköpta aktier av serie B har fulltecknats. Köpoptionerna kommer att överlåtas till ett pris av 7,10 SEK per köpoption vilket motsvarar marknadsvärde enligt en extern oberoende värdering utförd i enlighet med Black-Scholes-modellen. Lösenkursen för köpoptionerna uppgår till 117,90 SEK motsvarande 120 procent av den genomsnittliga aktiekursen under mätperioden 24 augusti - 7 september 2018. Varje köpoption berättigar till förvärv av en återköpt aktie av serie B under perioden från och med den 13 september 2021 till och med den 10 juni 2022. Stockholm den 25 september 2018 Bergman & Beving AB (publ) För ytterligare information kontakta: Peter Schön, CFO, telefon 070-339 89 99 Informationen lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 25 september 2018 kl. 10:00 CET. Ber

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board17.9.2018 08:00Pressmeddelande

Press Release 17 September 2018 Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board Immunicum AB (publ; IMMU.ST) announced today the appointment of leading oncology experts to its Scientific Advisory Board with the addition of Pawel Kalinski, MD, PhD, Vice Chair for Translational Research within the Department of Medicine at Roswell Park Comprehensive Cancer Center, and Inge Marie Svane, MD, PhD, Professor, Head of the Clinical Cancer Research programme, Faculty of Health Sciences, University of Copenhagen, Director, Centre for Cancer Immunotherapy (CCIT), and consultant in Oncology, Herlev University Hospital. Both Scientific Advisory Board members will serve as a strategic resource to Immunicum as the company continues to advance the clinical development of its lead product, ilixadencel. "We are honored to have such highly specialized experts in the field of immuno-oncology and cell therapy join our Scientific Advisory Board a

Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet17.9.2018 08:00Pressmeddelande

Pressmeddelande 17 september 2018 Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet Immunicum AB (publ; IMMU.ST) meddelade i dag att två ledande immun-onkologiska experter har valts in i bolagets vetenskapliga råd för att fungera som strategiska resurser för Immunicum under bolagets fortsatta kliniska utveckling av sin ledande produkt, ilixadencel. Pawel Kalinski, MD, PhD, vice ordförande för translationell forskning vid den medicinska institutionen vid Roswell Park Comprehensive Cancer Center, och Inge Marie Svane, MD, PhD, professor, chef för det kliniska cancerforskningsprogrammet på medicinska fakulteten vid Köpenhamns universitet, chef för Center för cancerimmunterapi (CCIT) samt överläkare inom onkologi, Herlevs universitetssjukhus har valts in i rådet. - Vi är hedrade att ha experter med specialistkompetens inom området immunonkologi och cellterapi i vårt vetenskapliga råd, vilka kan erbjuda ytterligare vägledning när det

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum